

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-64. (Canceled).

65. (Currently Amended) A method for diagnosing a pregnant woman at increased risk of preeclampsia ~~the diagnosis of preeclampsia~~ comprising the steps of:

a) obtaining a serum or plasma sample from ~~a~~ the woman in the second or third trimester of pregnancy;

b) contacting the sample with an antibody that specifically binds a marker, wherein the marker is a protein consisting of the amino acid sequence as presented in SEQ ID NO: 4;

~~c) b)~~ determining the amount of ~~a~~ the marker in the sample, ~~wherein the marker is selected from the group consisting of:~~

—— i. —— a protein having an amino acid sequence as presented in SEQ ID NO: 4;

—— ii. —— ~~a protein having an amino acid sequence exhibiting a sequence identity with any of the amino acid sequences according to i) of at least 95% over 100 amino acid residues;~~

—— iii. —— a nucleic acid encoding the amino acid of SEQ ID NO: 4;

—— iv. —— a nucleic acid having a sequence as presented in SEQ ID NO: 3;

and

—— v. —— ~~a nucleic acid having a sequence exhibiting a sequence identity with any of the nucleic acid sequences according to iv) of at least 95%;~~

d) e) comparing the determined amount of the marker with a reference amount derived from gestation age matched healthy women; and

e) ~~d)~~ establishing a diagnosis based on the result of step d) ~~e)~~, wherein a higher determined amount of the marker as compared to the reference amount of the marker is indicative of preeclampsia.

66. (Cancelled)

67. (Currently Amended) The method of claim 65, wherein the marker according to claim 65 is used in conjunction with a diagnostic agent for the measurement of expression of any of the ~~genes or~~ proteins selected from the group consisting of:

- a) EPAS-1/HIF-2 α ;
- b) neurokinin B;
- c) TIMP-1;
- d) VEGFR-1;
- e) VEGF;
- f) IGFBP-1;
- g) IGFBP-3;
- h) matrix metalloproteinase-2;
- i) leptin;
- j) PAI-1;
- k) IGF-1;
- l) angiopoietin-2;
- m) decorin;
- n) PIGF;
- o) HLA-G;
- p) HB-EGF;
- q) TGF- β 3;
- r) MIFR-2;
- s) LIM; and
- t) EBI3;

and/or diagnostic tools for the measurement of blood pressure or protein content of the urine.

68. (Cancelled).

69. (Currently Amended) A method of diagnosing a pregnant woman at increased risk of a disease selected from the group consisting of eclampsia; ~~pregnancy-induced hypertension; and~~ HELLP syndrome ~~and intrauterine growth retardation~~, comprising the steps of:

a) obtaining a serum or plasma sample from the pregnant woman in the second or third trimester of pregnancy;

b) contacting the sample with an antibody that specifically binds a marker, wherein the marker is a protein consisting of the amino acid sequence as presented in SEQ ID NO: 4;

c) b) determining the amount of a the marker in the sample ~~selected from the group consisting of:~~

—— i. —— a protein having an amino acid sequence as presented in SEQ ID NO: 4;

—— ii. —— a protein having an amino acid sequence exhibiting a sequence identity with any of the amino acid sequences according to i) of at least 95% over 100 amino acid residues;

—— iii. —— a nucleic acid encoding the amino acid of SEQ ID NO: 4;

—— iv. —— a nucleic acid having a sequence as presented in SEQ ID NO: 3;
and

—— v. —— a nucleic acid having a sequence exhibiting a sequence identity with any of the nucleic acid sequences according to iv) of at least 95%;

d) e) comparing the determined amount of the marker with a reference amount derived from gestation age matched healthy women; and

e) d) establishing a diagnosis based on the result of step d) e), wherein a higher determined amount of the marker as compared to the reference amount of the marker is

indicative of an increased risk of at least one of eclampsia, ~~pregnancy-induced hypertension, and~~
HELLP syndrome and ~~intrauterine growth retardation.~~

70. (Cancelled).

71. (Currently Amended) The method of claim 69, wherein the marker according to claim 69 is used in conjunction with a diagnostic agent for the measurement of expression of any of the ~~genes or~~ proteins selected from the group consisting of:

- a) EPAS-1/HIF-2 α ;
- b) neurokinin B;
- c) TIMP-1;
- d) VEGFR-1;
- e) VEGF;
- f) IGFBP-1;
- g) IGFBP-3;
- h) matrix metalloproteinase-2;
- i) leptin;
- j) PAI-1;
- k) IGF-1;
- l) angiopoietin-2;
- m) decorin;
- n) PIGF;
- o) HLA-G;
- p) HB-EGF;
- q) TGF- β 3;
- r) MIFR-2;
- s) LIM; and
- t) EBI3;

and/or diagnostic tools for the measurement of blood pressure or protein content of the urine.

72. (Cancelled).